Adaptimmune makes board appointment
This article was originally published in Scrip
Adaptimmune, a clinical-stage biotechnology company focused on the use of T-cell therapy to treat cancer, has named Lawrence (Larry) Alleva to its board of directors as an independent, non-executive director. Mr Alleva will also serve as chair of the board audit committee. Mr Alleva is a former partner of PricewaterhouseCoopers. He is currently a director for public companies Tesaro and Bright Horizons Family Solutions and for privately held Mirna Therapeutics.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.